Massachusetts official challenges Gilead’s hepatitis C drug prices

(Reuters) – Massachusetts’ attorney general is studying whether prices of Gilead Sciences’ blockbuster treatments for hepatitis C violate state law, according to a letter the prosecutor sent to the California-based drugmaker.